论文部分内容阅读
放疗在控制肿瘤方面是一种重要手段,并且已在技术、物理、肿瘤定位和治疗方面有了戏剧性的改善。用射线对肿瘤控制率获得了净增益。随着14年的临床评价,至今在化学修饰剂中,乏氧细胞辐射增敏剂已有十分广泛的研究。不幸的是,几乎所有Misonidagole(Miso)的Ⅲ期临床试用都没有导致疗效增加。Ⅱ期临床试用未获成功,就象一头死象重压在乏氧细胞增敏剂的进一步生物学和临床评价的前进道路上(见图),这不利于从持怀疑态度的临床医生和生物学家方面获得继续支持。虽然Miso不是最好的乏氧细胞辐射增敏剂,但它为类
Radiotherapy is an important tool in the control of cancer, and it has made dramatic improvements in technology, physics, tumor localization and treatment. The net gain in tumor control was achieved with rays. With 14 years of clinical evaluation, the radiosensitizers for hypoxic cells have been studied extensively in chemical modifiers to date. Unfortunately, almost all Phase III clinical trials of Misonidagole (Miso) did not result in increased efficacy. Phase II clinical trials have been unsuccessful, just as a dead elephant barge is on the way to further biological and clinical evaluation of hypoxic cell sensitizers (see figure), which is detrimental to skeptical clinicians and organisms. Scholars continue to support it. Although Miso is not the best hypoxic cell radiosensitizer, it is a class of